201 related articles for article (PubMed ID: 33206998)
1. Fifteen years of Na
Eagles DA; Chow CY; King GF
Br J Pharmacol; 2022 Jul; 179(14):3592-3611. PubMed ID: 33206998
[TBL] [Abstract][Full Text] [Related]
2. Sodium channels and pain: from toxins to therapies.
Cardoso FC; Lewis RJ
Br J Pharmacol; 2018 Jun; 175(12):2138-2157. PubMed ID: 28749537
[TBL] [Abstract][Full Text] [Related]
3. Reverse pharmacogenomics: carbamazepine normalizes activation and attenuates thermal hyperexcitability of sensory neurons due to Na
Yang Y; Adi T; Effraim PR; Chen L; Dib-Hajj SD; Waxman SG
Br J Pharmacol; 2018 Jun; 175(12):2261-2271. PubMed ID: 28658526
[TBL] [Abstract][Full Text] [Related]
4. Mutational analysis of ProTx-I and the novel venom peptide Pe1b provide insight into residues responsible for selective inhibition of the analgesic drug target Na
Rupasinghe DB; Herzig V; Vetter I; Dekan Z; Gilchrist J; Bosmans F; Alewood PF; Lewis RJ; King GF
Biochem Pharmacol; 2020 Nov; 181():114080. PubMed ID: 32511987
[TBL] [Abstract][Full Text] [Related]
5. Modulatory features of the novel spider toxin μ-TRTX-Df1a isolated from the venom of the spider Davus fasciatus.
Cardoso FC; Dekan Z; Smith JJ; Deuis JR; Vetter I; Herzig V; Alewood PF; King GF; Lewis RJ
Br J Pharmacol; 2017 Aug; 174(15):2528-2544. PubMed ID: 28542706
[TBL] [Abstract][Full Text] [Related]
6. Similar excitability through different sodium channels and implications for the analgesic efficacy of selective drugs.
Xie YF; Yang J; Ratté S; Prescott SA
Elife; 2024 Apr; 12():. PubMed ID: 38687187
[TBL] [Abstract][Full Text] [Related]
7. No gain, no pain: NaV1.7 as an analgesic target.
King GF; Vetter I
ACS Chem Neurosci; 2014 Sep; 5(9):749-51. PubMed ID: 25111714
[TBL] [Abstract][Full Text] [Related]
8. Alternative pain management via endocannabinoids in the time of the opioid epidemic: Peripheral neuromodulation and pharmacological interventions.
Lee MT; Mackie K; Chiou LC
Br J Pharmacol; 2023 Apr; 180(7):894-909. PubMed ID: 34877650
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive engineering of the tarantula venom peptide huwentoxin-IV to inhibit the human voltage-gated sodium channel hNa
Neff RA; Flinspach M; Gibbs A; Shih AY; Minassian NA; Liu Y; Fellows R; Libiger O; Young S; Pennington MW; Hunter MJ; Wickenden AD
J Biol Chem; 2020 Jan; 295(5):1315-1327. PubMed ID: 31871053
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and Evaluation of Novel α-Aminoamides Containing Benzoheterocyclic Moiety for the Treatment of Pain.
Tong K; Zhang R; Ren F; Zhang T; He J; Cheng J; Yu Z; Ren F; Zhang Y; Shi W
Molecules; 2021 Mar; 26(6):. PubMed ID: 33808667
[TBL] [Abstract][Full Text] [Related]
11. Analgesic potential of voltage gated sodium channel modulators for the management of pain.
McDougall JJ; O'Brien MS
Curr Opin Pharmacol; 2024 Apr; 75():102433. PubMed ID: 38277942
[TBL] [Abstract][Full Text] [Related]
12. GpTx-1 and [Ala
Chen C; Xu B; Shi X; Zhang M; Zhang Q; Zhang T; Zhao W; Zhang R; Wang Z; Li N; Fang Q
Br J Pharmacol; 2018 Oct; 175(20):3911-3927. PubMed ID: 30076786
[TBL] [Abstract][Full Text] [Related]
13. Emerging areas of opioid pharmacology.
Kelly E; Henderson G; Bailey CP
Br J Pharmacol; 2018 Jul; 175(14):2715-2716. PubMed ID: 29939423
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the Spider (
Gonçalves TC; Lesport P; Kuylle S; Stura E; Ciolek J; Mourier G; Servent D; Bourinet E; Benoit E; Gilles N
Toxins (Basel); 2019 Aug; 11(9):. PubMed ID: 31443554
[TBL] [Abstract][Full Text] [Related]
15. Identification and Characterization of ProTx-III [μ-TRTX-Tp1a], a New Voltage-Gated Sodium Channel Inhibitor from Venom of the Tarantula Thrixopelma pruriens.
Cardoso FC; Dekan Z; Rosengren KJ; Erickson A; Vetter I; Deuis JR; Herzig V; Alewood PF; King GF; Lewis RJ
Mol Pharmacol; 2015 Aug; 88(2):291-303. PubMed ID: 25979003
[TBL] [Abstract][Full Text] [Related]
16. Three Peptide Modulators of the Human Voltage-Gated Sodium Channel 1.7, an Important Analgesic Target, from the Venom of an Australian Tarantula.
Chow CY; Cristofori-Armstrong B; Undheim EA; King GF; Rash LD
Toxins (Basel); 2015 Jun; 7(7):2494-513. PubMed ID: 26134258
[TBL] [Abstract][Full Text] [Related]
17. Strategies towards safer opioid analgesics-A review of old and upcoming targets.
Varga BR; Streicher JM; Majumdar S
Br J Pharmacol; 2023 Apr; 180(7):975-993. PubMed ID: 34826881
[TBL] [Abstract][Full Text] [Related]
18. Nav1.7 and other voltage-gated sodium channels as drug targets for pain relief.
Emery EC; Luiz AP; Wood JN
Expert Opin Ther Targets; 2016 Aug; 20(8):975-83. PubMed ID: 26941184
[TBL] [Abstract][Full Text] [Related]
19. Targeting nociceptive transient receptor potential channels to treat chronic pain: current state of the field.
Moran MM; Szallasi A
Br J Pharmacol; 2018 Jun; 175(12):2185-2203. PubMed ID: 28924972
[TBL] [Abstract][Full Text] [Related]
20. Identification of Selective Acyl Sulfonamide-Cycloalkylether Inhibitors of the Voltage-Gated Sodium Channel (Na
Sun S; Jia Q; Zenova AY; Wilson MS; Chowdhury S; Focken T; Li J; Decker S; Grimwood ME; Andrez JC; Hemeon I; Sheng T; Chen CA; White A; Hackos DH; Deng L; Bankar G; Khakh K; Chang E; Kwan R; Lin S; Nelkenbrecher K; Sellers BD; DiPasquale AG; Chang J; Pang J; Sojo L; Lindgren A; Waldbrook M; Xie Z; Young C; Johnson JP; Robinette CL; Cohen CJ; Safina BS; Sutherlin DP; Ortwine DF; Dehnhardt CM
J Med Chem; 2019 Jan; 62(2):908-927. PubMed ID: 30499663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
